Lv1
30 积分 2024-12-13 加入
Abstract 3933: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
1小时前
已关闭
Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung
20天前
已关闭
Naxitamab: First Approval
4个月前
已完结
Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma
4个月前
已完结
皖公网安备34019202002308
